MISMATCH REPAIR DEFICIENCY
Clinical trials for MISMATCH REPAIR DEFICIENCY explained in plain language.
Never miss a new study
Get alerted when new MISMATCH REPAIR DEFICIENCY trials appear
Sign up with your email to follow new studies for MISMATCH REPAIR DEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy before surgery may help remove stubborn colon cancer
Disease control OngoingThis trial tests whether giving the immunotherapy drug camrelizumab before surgery can help completely remove T4 colon cancers that have a specific genetic feature (dMMR). These cancers often don't respond well to standard chemotherapy. The study will enroll 18 adults who will re…
Matched conditions: MISMATCH REPAIR DEFICIENCY
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Immune cell therapy shows promise for tough cancers
Disease control OngoingThis phase 2 study tests a personalized immune cell therapy called tumor-infiltrating lymphocytes (TIL) in 20 people with advanced solid cancers (like stomach, colon, or pancreatic cancer) that have not responded to standard treatments. Patients first receive chemotherapy to prep…
Matched conditions: MISMATCH REPAIR DEFICIENCY
Phase: PHASE2 • Sponsor: Udai Kammula • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Experimental cocktail aims to revive immune attack on Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of an experimental immune booster (N-803) with standard checkpoint inhibitors in people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease progressed after prior immunotherapy. The goal is to see if the combo can shrink tu…
Matched conditions: MISMATCH REPAIR DEFICIENCY
Phase: PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC